Nervous System, Pain and Mental Health: What the GPhC Assessment Tests

Scope and time budget

The area covers neurology, pain, psychiatry and substance misuse. It is also where medicines law bites hardest, because many of the drugs are controlled. A single scenario may need pharmacology, a prescription rule and a counselling point at the same time.

What is tested

• Epilepsy. Antiepileptic choice, interactions, enzyme induction and pregnancy.
• Valproate. The Pregnancy Prevention Programme and the restrictions on new starts.
• Parkinson's disease. Time-critical medicines and the danger of missed or delayed doses in hospital.
• Depression. SSRIs, discontinuation symptoms and serotonin syndrome.
• Antipsychotics. Clozapine monitoring and QT prolongation.
• Lithium. Monitoring, toxicity and interactions.
• Anxiety and insomnia. Benzodiazepines and z-drugs, dependence and driving.
• Opioids. Equivalent doses, constipation and dependence.
• Neuropathic pain. Gabapentinoids and their controlled-drug status.
• Migraine and headache. Acute and preventive treatment, and medication overuse headache.
• Dementia and delirium. Cholinesterase inhibitors and medicines to avoid.
• ADHD. Stimulant medicines and controlled-drug issues.
• Substance misuse. Methadone, buprenorphine, naloxone and alcohol dependence.
• Smoking cessation. Nicotine replacement and prescribed therapies.
• Analgesia. The analgesic ladder and OTC safety for paracetamol, NSAIDs and codeine.

UK guideline anchors

• Valproate (checked). No new starts under 55 years unless two specialists document the need, and a pregnancy prevention programme for those who could become pregnant.
• Controlled drugs (checked). Schedule 2 and 3 prescriptions need quantity in words and figures and a defined dose, and are valid for 28 days from the appropriate date.
• Schedules (to confirm). Gabapentin, pregabalin, tramadol and buprenorphine in Schedule 3, benzodiazepines and z-drugs in Schedule 4, and morphine, oxycodone and methylphenidate in Schedule 2.
• BNF and NICE. Dose ranges, interactions and treatment pathways. The BNFc applies for children.
• MHRA. Drug Safety Updates, for example on gabapentinoids and respiratory depression.

Epilepsy, valproate and pregnancy

Valproate is on the framework's list of high-risk drugs, so it is close to a certain topic. The checked rule is that, from January 2024, it must not be started in new patients younger than 55 years unless two specialists independently document that no other effective or tolerated treatment exists or that the reproductive risks do not apply. Girls and women who could become pregnant must be on a pregnancy prevention programme, and existing patients are reviewed with the revised Annual Risk Acknowledgement Form. Questions may ask what a pharmacist does when valproate is dispensed to a woman of childbearing potential: confirm the programme is in place, make sure she has the patient information, and do not tell her to stop suddenly. Seizure control matters, and abrupt withdrawal is itself a risk.

Enzyme-inducing antiepileptics such as carbamazepine and phenytoin reduce the effect of many drugs, including some hormonal contraceptives. Know this class of interaction, and learn the monitoring and counselling points for each antiepileptic from the BNF.

Opioids, gabapentinoids and controlled drugs

Opioid questions combine pharmacology with law. Know why constipation needs a laxative from the start, that opioid-naive patients and older patients need caution, and how equivalent doses are used when switching. Gabapentin and pregabalin became Schedule 3 controlled drugs in April 2019, with prescription-writing rules but, as we recall it, no safe-custody requirement. Tramadol is also Schedule 3. Confirm the schedule of each drug in current guidance. Dependence, diversion and overdose risk are common themes, as is the use of naloxone in opioid overdose.

Mental health medicines

For antidepressants, know the discontinuation symptoms, the features of serotonin syndrome and the interactions that cause it. For antipsychotics, know the monitoring for clozapine, the QT risk and metabolic effects. For lithium, know the signs of toxicity, the effect of dehydration, NSAIDs, ACE inhibitors and diuretics on levels, and the monitoring schedule. For benzodiazepines and z-drugs, know the short-term intent, dependence and the driving advice.

Children and older people

About one item in five involves a child, and nervous system medicines have specific paediatric points: weight-based paracetamol dosing, the avoidance of codeine in some groups, caution with stimulant medicines, and BNFc doses for antiepileptics. In older people, the questions turn to anticholinergic load, falls, sedatives and the risk of delirium. A good habit is to ask of every nervous system drug in a stem: is this patient very young, old, pregnant or on something that interacts?

Migraine, headache and OTC analgesia

Know the stepwise approach to acute migraine, the cautions that apply to triptans, and the risk of medication overuse headache with frequent analgesics. For OTC analgesia, know the safe maximum doses and the red flags that need referral, such as a sudden severe headache, neurological symptoms or headache after a head injury. Combination products containing codeine carry dependence and supply considerations.

Three typical traps

1. The abrupt-stop trap. Antiepileptics, corticosteroids, antidepressants and Parkinson's medicines should not be stopped abruptly. When the option is simply to stop, check why.
2. The interaction trap. Serotonergic combinations, enzyme inducers and QT-prolonging drugs are common hidden hazards in a medicines list.
3. The schedule trap. A drug that behaves like a controlled drug may sit in a different schedule from the one you assume, with different prescription and storage rules.

How to revise it

1. Group by safety rule. One line per drug class: the main risk, the monitoring and the counselling point.
2. Pair drug and law. For each controlled drug, learn the schedule and the prescription rule together.
3. Practise lists. Take medicines lists from a care home setting and look for sedative, anticholinergic and serotonergic load.
4. Revisit through calculations. Opioid conversions, infusion rates and weight-based doses.
5. Test with timed sets. Thirty mixed questions across epilepsy, mood, pain and substance misuse.

Continue with endocrine and infection. For the legal side, read UK law and guidelines. Back to the hub.